The Effect of Blood on the PC Ratio During Pregnancy
The Effect of Blood on the Protein to Creatine Ratio During Pregnancy
研究概览
详细说明
The Purpose of the Research:
The purpose of this study is to examine the effect of blood on the protein to creatine (PC) ratio in pregnant patients.
The Scientific or Scholarly Rationale:
The PC ratio is used to diagnosis proteinuria in pregnancy. It is thought that blood in the urine will cause the PC ratio to be elevated but there are no current studies to prove this hypothesis.
The Procedures to be Performed:
Upon presentation to the Labor and Delivery Triage or the Antepartum Unit, patients will be enrolled in the study. Urine collection that is not needed for medical workup will be collected and saved, and an extra 8 mLs of blood will be drawn during routine lab collection by phlebotomy team. Additional lab costs will be covered by Marshall Obstetrics & Gynecology.
Lab protocol: Divide urine into 4 different specimen cups with 20 mLs of urine each to measure urinalysis (UA) and PC ratio:
- UA and PC ratio on original sample
- UA and PC ratio with 1 mL of whole blood added
- UA and PC ratio with 2 mL of whole blood added
- UA and PC ratio with 5 mL of whole blood added
Subjects medical records will be reviewed for past obstetrical history after consent to be in the study.
The Risks and Potential Benefits of the Research:
Risks: 8 mLs of additional maternal blood will be drawn for study purposes. Possible risks could include pain, bleeding, fainting, bruising, infection, or hematoma (blood clot under the skin) at the injection site. Please note that routine blood would be drawn regardless of study enrollment.
Benefits: Our hypothesis is that the PC ratio will be elevated by contamination with blood. It is unknown if this hypothesis is correct.
Complete Inclusion/Exclusion Criteria (may be submitted separately if extensive):
Inclusion criteria includes patients presenting to Labor and Delivery Triage or Antepartum Unit at Cabell Huntington Hospital between the ages of 18 and approximately 45 years and gestational age of >20 weeks.
Exclusion criteria includes pre-existing proteinuria (excess protein in the urine) or hematuria (blood in the urine).
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jesse Cottrell, MD
- 电话号码:304-691-1400
- 邮箱:cottrellj@marshall.edu
研究联系人备份
- 姓名:Morgan Ruley, MS
- 电话号码:304-691-1458
- 邮箱:kelley115@marshall.edu
学习地点
-
-
West Virginia
-
Huntington、West Virginia、美国、25701
- 招聘中
- Marshall University School of Medicine
-
接触:
- Jesse Cottrell, MD
- 电话号码:304-691-1460
- 邮箱:cottrellje@marshall.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Labor and Delivery Triage or Antepartum Unit at Cabell Huntington Hospital between the ages of 18 and approximately 45 years and gestational age of >20 weeks
Exclusion Criteria:
- pre-existing proteinuria (excess protein in the urine) or hematuria (blood in the urine)
学习计划
研究是如何设计的?
设计细节
- 主要用途:放映
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:UA and PC ratio on original sample
Original urine sample
|
|
|
有源比较器:UA and PC ratio with 1 mL of whole blood added
1 mL of whole blood added to 20 mLs of urine
|
An additional 8 mL of blood will be drawn during routine lab collection
|
|
有源比较器:UA and PC ratio with 2 mL of whole blood added
2 mL of whole blood added to 20 mLs of urine
|
An additional 8 mL of blood will be drawn during routine lab collection
|
|
有源比较器:UA and PC ratio with 5 mL of whole blood added
5 mL of whole blood added to 20 mLs of urine
|
An additional 8 mL of blood will be drawn during routine lab collection
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To measure the PC ratio after whole blood has been serially added
大体时间:6 months
|
The PC ratio is used to diagnose proteinuria in pregnancy.
Our goal is to determine if blood causes the PC ratio to be elevated.
|
6 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.